The Efficacy and Safety of Bisoprolol in the Treatment of Myocardial Infarction with Cardiac Insufficiency

Identifying multi-target drugs for prostate cancer using machine learning-assisted transcriptomic analysis

Prostate cancer is a leading cause of cancer death in men, and the development of effective treatments is of great importance. This study explored to identify the candidate drugs for prostate cancer by transcriptomic data and CMap database analysis. After integrating the results of omics analysis, bisoprolol is confirmed as a promising drug. Moreover, cell experiment reveals its potential inhibitory effect on the proliferation of prostate cancer cells. Importantly, machine learning methods are employed to predict the targets of bisoprolol, and the dual-target ADRB3 and hERG are explored by dynamic simulation. The findings of this study demonstrate the potential of bisoprolol as a multi-target drug for prostate cancer treatment and the feasibility of using beta-adrenergic receptor inhibitors in prostate cancer treatment. In addition, the proposed research approach is promising for discovering potential drugs for cancer treatment by leveraging the concept of drug side effects leading to anticancer effects. Further research is necessary to investigate the pharmacological action, potential toxicity, and underlying mechanisms of bisoprolol in treating prostate cancer with ADRB3.Communicated by Ramaswamy H. Sarma.

Retracted: The Efficacy and Safety of Bisoprolol in the Treatment of Myocardial Infarction with Cardiac Insufficiency

[This retracts the article DOI: 10.1155/2022/3098726.].

Outcome effects of enalapril with or without bisoprolol in patients with acute myocardial infarction

OBJECTIVE

This study was designed to determine the effects of enalapril combined with bisoprolol on patients with acute myocardial infarction (AMI) and their prognosis.

METHODS

This study retrospectively analyzed data of 104 patients receiving AMI treatment in the First People's Hospital of Shanghai from May 2019 to October 2021, including 48 patients treated with enalapril alone (control group) and 56 patients treated with enalapril combined with bisoprolol (observation group). The efficacy, adverse reactions, cardiac function [left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVED), left ventricular end-systolic diameter (LVES) and left ventricular mass (LVM)] of the two groups were measured and analyzed. The patients were followed up for one year to compare their prognosis.

RESULTS

The observation group showed a significantly higher total response rate than the control group (P < 0.05), but the incidence of adverse reactions was not different significantly between the two groups (P > 0.05). After treatment, LVES, LVED and LVEF increased significantly in both groups (P < 0.05), and the observation group showed significantly lower LVES and LVM levels and had a higher LVEF level than the control group (P < 0.05). The follow-up results revealed no significant difference in prognosis and survival between the two groups (P > 0.05).

CONCLUSION

Enalapril combined with bisoprolol is effective and safe in the treatment of AMI, because this regimen can effectively improve patients' cardiac function.